USPTO Examiner ALLEN MARIANNE P - Art Unit 1647

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19033679ANTIBODIES TARGETING IL3January 2025May 2025Allow411NoNo
19005529TL1A BINDING PROTEINS AND METHODS OF USEDecember 2024September 2025Allow821YesNo
18988612SELECTIVE AND POTENT INHIBITORY ANTIBODIES OF MYOSTATIN ACTIVATIONDecember 2024April 2025Allow410NoNo
18979795ANTIBODIES THAT BIND INTERLEUKIN 13 AND METHODS OF USEDecember 2024May 2025Allow511YesNo
18964217ANTI-FGF23 ANTIBODY OR ANTIBODY FRAGMENT THEREOFNovember 2024December 2025Allow1321NoNo
18772062TMEM219 ANTIBODIES AND THERAPEUTIC USES THEREOFJuly 2024October 2024Allow310NoNo
18753823Albumin Bound Macromolecule Tri-Agonist Activating GLP-1/GIP/Glucagon ReceptorsJune 2024December 2025Allow1831NoNo
18642478APPLICATION OF A NANOBODY TARGETING ON IL-6RAApril 2024January 2025Allow920NoNo
18594400TIGIT- AND LIGHT-BASED CHIMERIC PROTEINSMarch 2024October 2025Abandon2001NoNo
18593108ANTI-HUMAN INTERLEUKIN-33 MONOCLONAL ANTIBODY AND USE THEREOFMarch 2024March 2025Allow1220NoNo
18436546METHODS FOR THE TREATMENT OF SCLERODERMA AND RELATED CONDITIONSFebruary 2024October 2025Abandon2001NoNo
18429738Method for Producing an Active Hepatocyte Growth Factor (HGF)February 2024May 2025Allow1610NoNo
18420510ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USEJanuary 2024November 2025Abandon2111NoNo
18410568DUAL CYTOKINE FUSION PROTEINS COMPRISING MULTI-SUBUNIT CYTOKINESJanuary 2024July 2025Abandon1801NoNo
18391233COMPOSITIONS, DOSES, AND METHODS FOR TREATMENT OF THYROID EYE DISEASEDecember 2023July 2025Allow1910YesNo
18485838Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologiesOctober 2023August 2025Abandon2201NoNo
18451780ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCERAugust 2023January 2026Abandon2911NoNo
18448425SEROLOGICAL BIOMARKERS FOR EARLY DIAGNOSIS OF LUNG CANCERAugust 2023August 2025Abandon2410NoNo
18448054Heparin-Associated Polypeptides and Uses ThereofAugust 2023May 2024Abandon910NoNo
18358849ANTI-4-1BB ANTIBODIES AND METHODS OF MAKING AND USING THEREOFJuly 2023March 2026Allow3230YesNo
18339713ANTIBODY THAT BINDS TO VEGF-A AND ANG2 AND METHODS OF USEJune 2023August 2025Allow2510NoNo
18339094ANTIGEN-BINDING MOLECULES AND USES THEREOFJune 2023April 2024Allow911NoNo
18327544COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF CORNEAL HAZE AND SCARRINGJune 2023February 2026Abandon3220NoNo
18322927HEAVY CHAIN ONLY ANTIBODIES TO PDGFMay 2023March 2025Abandon2210NoNo
18197190FGF21 MIMETIC ANTIBODIES AND USES THEREOFMay 2023July 2025Abandon2620NoNo
18311771ANTI-CD28 X ANTI-PSMA ANTIBODIESMay 2023January 2024Allow910NoNo
18311082LIVER-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOFMay 2023October 2024Allow1821YesNo
18307729COMPOSITIONSApril 2023March 2025Abandon2310NoNo
18304598ANTI C-MET ANTIBODIESApril 2023May 2025Allow2511NoNo
18295201True human antibody specific for interleukin 1 alphaApril 2023October 2025Allow3000NoNo
18173549Liquid Formulation of a VEGF AntagonistFebruary 2023October 2025Allow3220NoNo
18172987ANTI-CD28 X ANTI-PSMA ANTIBODIESFebruary 2023January 2025Allow2321NoNo
18165515EGFR x CD28 MULTISPECIFIC ANTIBODIESFebruary 2023May 2025Allow2700NoNo
18164351IL10 RECEPTOR BINDING MOLECULES AND METHODS OF USEFebruary 2023July 2024Allow1721NoNo
18040042ANTI-TRKA ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, PREPARATION METHOD THEREOF, AND APPLICATION THEREOFJanuary 2023December 2025Allow3510NoNo
18018448IL12 RECEPTOR SYNTHETIC CYTOKINES AND METHODS OF USEJanuary 2023December 2024Allow2341NoNo
18160355METHODS AND AGENTS FOR THE TREATMENT OF OCULAR DISEASEJanuary 2023November 2024Allow2210NoNo
18006831IL10RA BINDING MOLECULES AND METHODS OF USEJanuary 2023January 2025Allow2441YesNo
18017838IL10Ra/IL2Ry SYNTHETIC CYTOKINESJanuary 2023March 2025Allow2641NoNo
18017836IL2RB/IL2RG SYNTHETIC CYTOKINESJanuary 2023November 2024Abandon2231NoNo
18155644ETAR ANTIBODY, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOFJanuary 2023November 2025Allow3421NoNo
18147181PROTEIN SECRETORY FACTOR WITH HIGH SECRETORY EFFICIENCY AND AN EXPRESSION VECTOR COMPRISING THE SAMEDecember 2022August 2025Abandon3120NoNo
18087045MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USESDecember 2022December 2025Allow3530YesNo
18068977CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIESDecember 2022December 2024Abandon2410NoNo
18065504DUAL CYTOKINE FUSION PROTEINS COMPRISING MULTI-SUBUNIT CYTOKINESDecember 2022January 2024Abandon1301NoNo
18077137Bispecific Anti-PSMA x Anti-CD28 Antibodies and Uses ThereofDecember 2022June 2025Allow3020NoNo
18071057FULLY HUMANIZED ANTI-PLATELET FACTOR 4 ANTIBODIES THAT TREAT HEPARIN-INDUCED THROMBOCYTOPENIANovember 2022October 2024Allow2220NoNo
18059677COMBINATION OF TWO OR MORE ANTI-C5 ANTIBODIES AND METHODS OF USENovember 2022February 2026Abandon3901NoNo
17990497METHOD FOR EXTENDING HALF-LIFE OF A PROTEINNovember 2022September 2024Abandon2201NoNo
17990492METHOD FOR EXTENDING HALF-LIFE OF A PROTEINNovember 2022August 2024Abandon2101NoNo
17990507METHOD FOR EXTENDING HALF-LIFE OF A PROTEINNovember 2022October 2024Abandon2201NoNo
17990478METHOD FOR EXTENDING HALF-LIFE OF A PROTEINNovember 2022August 2024Abandon2101NoNo
17990438METHOD FOR EXTENDING HALF-LIFE OF A PROTEINNovember 2022September 2024Abandon2201NoNo
17990460METHOD FOR EXTENDING HALF-LIFE OF A PROTEINNovember 2022August 2024Abandon2101NoNo
17990515METHOD FOR EXTENDING HALF-LIFE OF A PROTEINNovember 2022October 2024Abandon2201NoNo
17997582RED LIGHT-CONTROLLED PROTEIN DIMERIZATION SYSTEMSOctober 2022March 2026Allow4021NoNo
17920549PROTEIN DEGRADATIONOctober 2022February 2026Abandon4001NoNo
17961502METHOD OF STIMULATING ASYMMETRIC DIVISION OF SATELLITE STEM CELLSOctober 2022November 2025Abandon3721NoNo
17939238RECOMBINANT MODIFIED FIBROBLAST GROWTH FACTORS AND THERAPEUTIC USES THEREOFSeptember 2022February 2026Allow4130YesNo
17801624WNT SUPER AGONISTSAugust 2022February 2026Abandon4101NoNo
17818798COMPOSITIONS, DOSES, AND METHODS FOR TREATMENT OF THYROID EYE DISEASEAugust 2022January 2024Abandon1710NoNo
17760300CORONA VIRUS BINDERSAugust 2022January 2026Abandon4101NoNo
17760252PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ANTIBODIES, CONJUGATES, COMPOSITIONS, AND USES THEREOFAugust 2022February 2026Abandon4201NoNo
17850135ANTI-ACTH ANTIBODIES AND USE THEREOFJune 2022March 2025Allow3211NoNo
17850339CYSTEINE LINKED NANOBODY DIMERSJune 2022April 2025Allow3421NoNo
17757953TGF-BETA-RII BINDING PROTEINSJune 2022December 2025Allow4210NoNo
17807939ARTHRITIS TREATMENTJune 2022June 2024Allow2410NoNo
17842904ANTI-ANGPT2 ANTIBODIESJune 2022May 2024Allow2310NoNo
17785229CANINE INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODIESJune 2022October 2025Allow4010NoNo
17834703ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCEJune 2022November 2025Allow4151NoNo
17756896LIQUID PREPARATION CONTAINING ANTI-IL-17 ANTIBODYJune 2022January 2026Allow4420NoNo
17831398ANTI-CCR8 ANTIBODIES AND USES THEREOFJune 2022October 2024Allow2921NoNo
17778814IGFBP3 ANTIBODIES AND THERAPEUTIC USES THEREOFMay 2022March 2026Abandon4611NoNo
17748405COMPOUNDS AND METHODS TARGETING EPIREGULINMay 2022December 2025Allow4340YesNo
17777021TMEM219 ANTIBODIES AND THERAPEUTIC USES THEREOFMay 2022September 2024Abandon2801NoNo
17737343A Method for Producing An Active Hepatocyte Growth Factor (HGF)May 2022June 2024Abandon2510NoNo
17727120FGF21 COMPOSITIONS FOR TREATMENT OR PREVENTION OF NEOVASCULARIZATION OF THE EYE AND METHODS THEREFORApril 2022February 2026Allow4631NoNo
17770420COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCERApril 2022November 2025Abandon4301NoNo
17724639COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASEApril 2022February 2023Abandon1011NoNo
17719496IMMUNOGLOBULIN VARIABLE DOMAINSApril 2022March 2023Allow1130NoNo
17766131Antigen Specific Binding Domains and Antibody MoleculesApril 2022November 2025Abandon4310NoNo
17702890MONOCLONAL ANTIBODIES TO ANGIOTENSIN-(1-12), COMPOSITIONS INCLUDING THE SAME, AND METHODS OF USE THEREOFMarch 2022March 2025Allow3631YesNo
17703585INSULIN-LIKE GROWTH FACTOR-CHEMOTHERAPEPUTIC CONJUGATE FOR TREATING MYELODYSPLASTIC SYNDROMEMarch 2022September 2025Allow4230NoNo
17699925ANGIOPOIETIN-LIKE 4 ANTIBODIES AND METHODS OF USEMarch 2022June 2024Abandon2720NoNo
17697508IMMUNOGLOBULIN VARIABLE DOMAINSMarch 2022January 2026Allow4641NoYes
17761128GIPR ANTIBODY AND FUSION PROTEIN BETWEEN SAME AND GLP-1, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOFMarch 2022November 2025Abandon4410NoNo
17654318METHODS FOR THE TREATMENT OF THYROID EYE DISEASEMarch 2022January 2026Allow4641YesNo
17691468VACCINE COMPOSITIONS COMPRISING C-C MOTIF CHEMOKINE 22 (CCL22) OR FRAGMENTS THEREOFMarch 2022October 2025Allow4331NoNo
17678861METHODS AND AGENTS FOR THE TREATMENT OF OCULAR DISEASEFebruary 2022November 2022Allow920NoNo
17592375Cancer Antigen PeptideFebruary 2022September 2023Abandon1901NoNo
17592381Cancer Antigen PeptideFebruary 2022October 2023Abandon2001NoNo
17592384Cancer Antigen PeptideFebruary 2022October 2023Abandon2001NoNo
17586620METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSISJanuary 2022November 2023Abandon2201NoNo
17583503HIGHLY CONCENTRATED FORMULATIONS OF SOLUBLE Fc RECEPTORSJanuary 2022March 2024Allow2611NoNo
17579376Humanized Anti-VEGF Monoclonal AntibodyJanuary 2022March 2024Allow2620NoNo
17562499IMMUNOGLOBULIN VARIABLE DOMAINSDecember 2021June 2022Allow510NoNo
17559808ANTI-ANGPTL 3/8 COMPLEX ANTIBODIES AND METHODS OF USING THE SAMEDecember 2021August 2024Allow3220NoNo
17621414ANTIBODIES AND ASSAYS FOR CCL14December 2021October 2025Abandon4501NoNo
17556193Modulation of Heparin-Binding Epidermal Growth Factor Activity for Tympanic Membrane HealingDecember 2021March 2024Allow6020NoNo
17539335METHODS OF TREATING FGF21-ASSOCIATED DISORDERSDecember 2021June 2023Allow1910NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ALLEN, MARIANNE P.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
18
Examiner Affirmed
17
(94.4%)
Examiner Reversed
1
(5.6%)
Reversal Percentile
21.9%
Lower than average

What This Means

With a 5.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
119
Allowed After Appeal Filing
13
(10.9%)
Not Allowed After Appeal Filing
106
(89.1%)
Filing Benefit Percentile
14.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 10.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ALLEN, MARIANNE P - Prosecution Strategy Guide

Executive Summary

Examiner ALLEN, MARIANNE P works in Art Unit 1647 and has examined 1,180 patent applications in our dataset. With an allowance rate of 51.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.

Allowance Patterns

Examiner ALLEN, MARIANNE P's allowance rate of 51.8% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ALLEN, MARIANNE P receive 2.28 office actions before reaching final disposition. This places the examiner in the 64% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ALLEN, MARIANNE P is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +25.0% benefit to allowance rate for applications examined by ALLEN, MARIANNE P. This interview benefit is in the 72% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 21.8% of applications are subsequently allowed. This success rate is in the 26% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 50.3% of cases where such amendments are filed. This entry rate is in the 76% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 73.5% of appeals filed. This is in the 62% percentile among all examiners. Of these withdrawals, 82.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 73.1% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 5.4% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.2% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.